Acutaas ChemicalQ2 FY24

Acutaas Chemical Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,942.9P/E: 73.5Market Cap: ₹32.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • FY24 revenue growth target revised downward to 18%-22% from earlier 22%-25%, mainly due to pricing erosion despite volume growth of 20%-25%.
  • Volume growth expected to remain strong; value/realization affected by pricing pressures.
  • Muted performance expected in FY24 due to delayed product launches and acquisition/integration of Baba Fine Chemicals; FY25 anticipated to be better than both FY23 and FY24.
  • Baba Fine Chemicals integration year in FY24; exponential growth targeted in coming years with aim for Rs. 200-250 crore topline in 4-5 years.
  • Full utilization of Ankleshwar facility capacity targeted by FY27 with ongoing pipeline discussions.
  • Specialty chemicals segment targeting to achieve 2.5x growth over next couple of years.
  • New product launches (e.g., UV absorber, electrolyte additives) expected to contribute revenue from Q3 FY24 onwards.
  • Fermion contract revenues expected to ramp up fully by H2 FY25.

See what Acutaas Chemical management said on margin guidance — free account, 30 seconds.

Fundraise plans

- There is no explicit mention of any current or planned new fundraising through debt or equity in the Q2 FY24 earnings call transcript. - The company has ongoing CAPEX plans, including a 16-megawatt solar power plant project with a CAPEX of around Rs. 65-70 crores and Ankleshwar facility expansion, with Rs. 100-110 crores expected by year-end. - No specific discussions or announcements about raising funds via debt or equity were made during the call. - Management focused on operational updates, acquisitions (Baba Fine Chem), pricing pressures, and growth prospects without addressing new capital raising. - For any missed or follow-up queries, management suggested contacting their IR advisor (E&Y), indicating no immediate public fundraising announcements. Hence, based on the available transcript till November 9, 2023, there is no current or near-future fundraising indicated.

See what Acutaas Chemical management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Ami Organics has approved a 16-megawatt captive solar power plant project with a CAPEX of approximately Rs. 65-70 crores; installation is expected to complete by the end of the financial year.
  • Additionally, a 5-megawatt solar power plant is already in progress, which will help offset electricity expenses once operational.
  • CAPEX for H1 FY24 was Rs. 105 crores, with another Rs. 100-110 crores expected by year-end.
  • The Ankleshwar facility, acquired from Gujarat Organics with an investment of around Rs. 190 crores, will be operational by mid-December 2023, ramping up in Q4 FY24 to contribute to revenues.
  • The Ankleshwar site's capacity includes 33% allocated to the Fermion contract (fully booked) with 66% capacity free for future demand till FY27.
  • Ongoing focus on expanding strategic partnerships and commercial supplies—e.g., the Fermion contract with plans to start supplying two more intermediates commercially in H2 FY25.

Track Acutaas Chemical — get its next earnings analysis in your feed

How does Acutaas Chemical rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisAcutaas Chemical
Rev 3Mar 3

How does Acutaas Chemical rank in Pharmaceuticals & Biotechnology?

Compare Acutaas Chemical against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →